Cerecor Inc (CERC) Stock Price, Quote, News and Overview
NASDAQ:CERC - Nasdaq -
CERC Quote, Performance and Key Statistics
2.93
-0.05 (-1.68%)
The current stock price of CERC is 2.93 null. In the past month the price increased by 6.55%. In the past year, price increased by 15.35%.
CERC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.39 | 722.35B | ||
| JNJ | JOHNSON & JOHNSON | 16.44 | 395.46B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.69 | 288.46B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 12.9 | 220.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.8 | 213.06B | ||
| MRK | MERCK & CO. INC. | 10.18 | 199.15B | ||
| PFE | PFIZER INC | 7.56 | 137.93B | ||
| SNY | SANOFI-ADR | 10.56 | 116.71B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.36 | 95.02B | ||
| GSK | GSK PLC-SPON ADR | 8.15 | 73.23B | ||
| ZTS | ZOETIS INC | 24.48 | 65.61B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.78 | 45.11B |
Related stock screener links
About CERC
Company Profile
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2015-11-13. The firm is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The firm is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
Company Info
Cerecor Inc
540 Gaither Rd Ste 400
Rockville MARYLAND 20850 US
CEO: Michael Cola
Employees: 32
Phone: 14105228707.0
Cerecor Inc / CERC FAQ
What is the stock price of Cerecor Inc today?
The current stock price of CERC is 2.93 null. The price decreased by -1.68% in the last trading session.
What is the ticker symbol for Cerecor Inc stock?
The exchange symbol of Cerecor Inc is CERC and it is listed on the Nasdaq exchange.
On which exchange is CERC stock listed?
CERC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Cerecor Inc stock?
4 analysts have analysed CERC and the average price target is 6.63 null. This implies a price increase of 126.28% is expected in the next year compared to the current price of 2.93. Check the Cerecor Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Cerecor Inc worth?
Cerecor Inc (CERC) has a market capitalization of 281.31M null. This makes CERC a Micro Cap stock.
How many employees does Cerecor Inc have?
Cerecor Inc (CERC) currently has 32 employees.
What are the support and resistance levels for Cerecor Inc (CERC) stock?
Cerecor Inc (CERC) has a support level at 2.84 and a resistance level at 2.94. Check the full technical report for a detailed analysis of CERC support and resistance levels.
Is Cerecor Inc (CERC) expected to grow?
The Revenue of Cerecor Inc (CERC) is expected to decline by -12.27% in the next year. Check the estimates tab for more information on the CERC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Cerecor Inc (CERC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CERC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CERC, evaluating the profitability, health, valuation and growth aspects
- Cerecor Inc (CERC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Cerecor Inc (CERC) Sales and EPS estimates to see what analysts future expectations are.
- Cerecor Inc (CERC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Cerecor Inc (CERC) Insider and Institutional Ownership to learn about the owners and their transactions.
- Cerecor Inc (CERC) Stock Chart to make your own analysis
- Cerecor Inc (CERC) Latest news and press-releases to stay up to date.
Does Cerecor Inc (CERC) stock pay dividends?
CERC does not pay a dividend.
What is the Price/Earnings (PE) ratio of Cerecor Inc (CERC)?
Cerecor Inc (CERC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
CERC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CERC. When comparing the yearly performance of all stocks, CERC turns out to be only a medium performer in the overall market: it outperformed 48.14% of all stocks.
CERC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CERC. CERC may be in some trouble as it scores bad on both profitability and health.
CERC Financial Highlights
Over the last trailing twelve months CERC reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS decreased by -49.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1194.83% | ||
| ROA | -119.98% | ||
| ROE | N/A | ||
| Debt/Equity | 0.79 |
CERC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 100% to CERC. The Buy consensus is the average rating of analysts ratings from 4 analysts.
For the next year, analysts expect an EPS growth of 4.09% and a revenue growth -12.27% for CERC